Damora Therapeutics, Inc. quarterly report, Q3 FY2022

Business Context and Reporting Period

The filing is Galecto, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2022. The request metadata identifies Damora Therapeutics, Inc., but the filing itself identifies the registrant as Galecto, Inc. (Nasdaq: GLTO).

Galecto is a clinical-stage biotechnology company developing small-molecule inhibitors of galectin-3 and LOXL2 for fibrotic diseases and cancer. Its principal candidates are GB0139, GB2064 and GB1211, all in Phase 2 development. The company has no approved products and generated no product revenue.

Financial Metrics

MetricThree months ended September 30, 2022Nine months ended September 30, 2022Comparable 2021 period
Revenue$0$0$0
Research and development expense$10.5 million$37.4 million$9.7 million and $28.4 million
General and administrative expense$3.1 million$10.2 million$3.2 million and $10.4 million
Total operating expenses$13.6 million$47.7 million$12.9 million and $38.8 million
Net loss$13.7 million$47.6 million$12.7 million and $38.3 million
Net loss per share$0.54$1.88$0.50 and $1.52
  • Operating margin and gross margin are not meaningful because the company had no revenue and all operating costs were related primarily to research and development and administration.
  • Research and development represented approximately 78% of total operating expenses for the nine-month period, compared with approximately 73% in the prior-year period.
  • Cash, cash equivalents and marketable securities totaled $75.9 million at September 30, 2022, compared with $109.2 million at December 31, 2021.
  • Cash and cash equivalents were $28.3 million; current assets were $71.2 million and current liabilities were $8.9 million.
  • Total liabilities were $9.3 million, consisting primarily of accounts payable, accrued expenses and operating lease liabilities. The filing does not report funded debt.
  • Accumulated deficit was $203.7 million at September 30, 2022.
  • Net cash used in operating activities was $31.5 million for the first nine months of 2022, compared with $34.5 million in the prior-year period.
  • Net cash used in investing activities was $1.9 million, principally reflecting purchases and sales of marketable securities. Financing activities provided $0.4 million from common-stock issuances.

Material Changes Versus the Prior Comparable Period

  • Third-quarter research and development expense increased 7.7% to $10.5 million, primarily because of higher clinical-trial spending.
  • Nine-month research and development expense increased 31.9% to $37.4 million. Clinical-trial-related costs increased by $8.5 million, while chemistry, manufacturing and control costs declined by $1.3 million.
  • Nine-month total operating expenses increased 23.0% to $47.7 million, and net loss increased 24.0% to $47.6 million.
  • General and administrative expense was broadly stable, declining 1.3% for the nine-month period.
  • Cash and marketable securities declined by approximately $33.3 million from year-end 2021, primarily reflecting operating cash burn and foreign-exchange effects.
  • The company sold 319,197 shares through its at-the-market program during the first nine months, generating $0.4 million net proceeds. The weighted-average selling price was $1.99 per share.
  • Stock-based compensation increased to $4.2 million from $3.2 million for the first nine months.

Guidance, Outlook, Commentary, Risks and Unusual Items

  • Management expects continued net losses and increasing research and development, general and administrative and capital expenditures for the foreseeable future.
  • Based on its current operating plan, management expects the $75.9 million of cash, cash equivalents and marketable securities at September 30, 2022 to fund operations into the second half of 2024. This estimate is subject to significant assumptions, and additional financing will be required thereafter or sooner if spending or development timing changes.
  • GB0139’s GALACTIC-1 Phase 2b trial completed target enrollment of 141 patients in the second quarter of 2022; topline results were expected in mid-2023.
  • GB2064’s MYLOX-1 Phase 2a trial reported an interim assessment in which four of five evaluable patients experienced at least a one-grade reduction in bone-marrow collagen fibrosis. Sixteen patients had been dosed, with eight completing or continuing treatment and eight discontinuing because of adverse events or disease progression. Topline results were expected in the second half of 2023.
  • GB1211’s GALLANT-1 Phase 2a trial in combination with atezolizumab began in the second quarter of 2022, with topline results expected in the second half of 2023.
  • After the reporting period, the company disclosed positive topline biomarker results from the GULLIVER-2 liver-cirrhosis trial, including statistically significant reductions in ALT, AST and GGT. The filing reported no treatment-related serious adverse events in the highlighted subgroup; one patient in the overall GB1211 population experienced serious adverse events deemed unrelated to treatment.
  • COVID-19 and its variants continued to create risks for patient recruitment, clinical-trial timing, supply chains and service providers.
  • Key risks include clinical and regulatory failure, inability to obtain additional financing, dilution from future equity offerings, dependence on third-party manufacturers and clinical providers, intellectual-property challenges, competition, dependence on key personnel and uncertain product-market acceptance.
  • The company reported no material legal proceedings, no material changes to previously disclosed risk factors and no material changes to commitments and contingencies.
  • Management concluded that disclosure controls and procedures were effective at the reasonable assurance level, with no material change in internal control over financial reporting during the quarter.

Important Facts for Investors to Verify

  • Confirm the registrant identity: the supplied filing is for Galecto, Inc., not Damora Therapeutics, Inc.
  • Verify the cash runway assumptions supporting management’s expectation of funding into the second half of 2024.
  • Track the timing, enrollment, safety and efficacy readouts for GALACTIC-1, MYLOX-1, GALLANT-1 and GULLIVER-2.
  • Assess the pace of quarterly cash burn and the potential need for equity, debt, licensing or collaboration financing.
  • Monitor dilution risk from the $50.0 million at-the-market program and outstanding stock options; 5.8 million options were outstanding at September 30, 2022.
  • Evaluate whether interim biomarker and fibrosis findings translate into clinically meaningful outcomes and regulatory approval.
  • Review the impact of COVID-19, trial enrollment delays, manufacturing dependencies and other risks incorporated by reference from the 2021 Form 10-K.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.